MVA-BN Publications

Overton ET, Lawrence SJ, Wagner E, Nopora K, Rösch S, Young P, et al.

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

PLoS ONE 13(4): e0195897.
Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, et al.

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

PLoS ONE. 2016 11(6): e0157335.
Greenberg RN, Hurley Y, Dinh DV, Mraz S, Vera JG, von Bredow D, et al.

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

PLoS ONE 10(10): e0138348.
Zitzmann-Roth E-M, von Sonnenburg F, de la Motte S, Arndtz-Wiedemann N, von Krempelhuber A, Uebler N, et al.

Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population

PLoS ONE. 2015; 10(4):e0122653. doi:10.1371/journal.pone.0122653
Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, Wagner E, von Krempelhuber A, Virgin G, Meyer TP, Müller J, Bädeker N, Grünert R, Young P, Rösch S, Maclennan J, Arndtz-Wiedemann N, Chaplin P.

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.

Open Forum Infect Dis. 2015 May 5;2(2):ofv040. doi: 10.1093/ofid/ofv040.
von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, Vollmar J, Roesch S, Baedeker N, Kollaritsch H, Chaplin P

Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis

Vaccine. 2014 Sep 29;32(43):5696-702. doi: 10.1016/j.vaccine.2014.08.022. Epub 2014 Aug 20.
Frey SE, Winokur PL . et al.

Safety and immunogenicity of IMVAMUNE(®) smallpox vaccine using different strategies for a post event scenario

Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050.
Hatch GJ, Graham VA, et al.

Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques.

J Virol. 2013 Jul;87(14):7805-15. doi: 10.1128/JVI.03481-12.
Townsend MB, Keckler MS, et al.:

Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.

J Virol. 2013 Jan;87(2):900-11. doi: 10.1128/JVI.02089-12.
Walsh SR, Wilck MB, et al.:

Safety and immunogenicity of modified vaccinia ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

J Infect Dis. 2013 Jun 15;207(12):1888-97. doi: 10.1093/infdis/jit105.
Keckler MS, Carroll DS, et al.:

Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.

J Virol. 2011 Aug;85(15):7683-98. doi: 10.1128/JVI.02174-10.
von Krempelhuber A, Vollmar J, et al.

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Vaccine. 2010 Feb 3;28(5):1209-16. doi: 10.1016/j.vaccine.2009.11.030.
Wolff MW, Siewert C, et al.

Capturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers.

Biotechnol Bioeng. 2010 Mar 1;105(4):761-9. doi: 10.1002/bit.22595.
Garza NL, Hatkin JM, et al.

Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.

Vaccine. 2009 Sep 4;27(40):5496-504. doi: 10.1016/j.vaccine.2009.06.105.
Kennedy JS, Greenberg RN

IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.

Expert Rev Vaccines. 2009 Jan;8(1):13-24. doi: 10.1586/14760584.8.1.13.
Sano J, Chaitman BR, et al.

Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination.

Am J Med. 2009 Jan;122(1):79-84. doi: 10.1016/j.amjmed.2008.07.025.
Jones T

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Curr Opin Mol Ther. 2008 Aug;10(4):407-17.
Frey SE, Newman FK, et al.

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Vaccine. 2007 Dec 12;25(51):8562-73.
Vollmar J, Arndtz N, et al.

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.

Vaccine. 2006 Mar 15;24(12):2065-70.